Our findings establish a novel mechanism in which ATG7 regulates cholesterol metabolism and crosstalk between MHC-I and ROS/ NF-кB, which together mediate CRC immunotherapy and provide a potential biomarker for clinically predicting the therapeutic effect of PD-1/PD-L1 blockade. The gene discussed is ATG7; the disease is colorectal carcinoma.